Losartan-induced sprue-like enteropathy: A case report

Authors

DOI:

https://doi.org/10.22516/25007440.1532

Keywords:

Losartán, angiotensin II receptor antagonists, diarrhea

Abstract

Introduction: Sprue-like enteropathy induced by angiotensin II receptor antagonists (ARBs) is an uncommon entity, initially described with olmesartan and later with other drugs in the same class. It is characterized by chronic diarrhea, weight loss, and histological changes similar to celiac disease, but with negative serology.

Case presentation: We present the case of a 75-year-old woman receiving long-term treatment with losartan who developed diarrhea and progressive weight loss. Duodenal biopsies showed villous atrophy and chronic inflammation. After discontinuing the drug, the patient achieved complete clinical resolution.

Discussion: The differential diagnosis includes refractory celiac disease, inflammatory bowel disease, and infectious enteropathies. The key finding is the temporal relationship with drug use, the absence of positive serology for celiac disease, and resolution of symptoms after withdrawing the ARB.

Conclusion: This case reinforces the importance of considering ARB-induced enteropathy in the differential diagnosis of chronic diarrhea, especially in the presence of negative celiac serology.

Downloads

Download data is not yet available.

Author Biographies

Siomara Aransuzú Chávez Sánchez, Clínica San Felipe

Gastroenterologist, Clínica San Felipe, Lima, Peru.

Jorge Luis Espinoza Ríos, Clínica San Felipe

Gastroenterologist, Clínica San Felipe, Lima, Peru.

José Luis Pinto Valdivia, Clínica San Felipe

Gastroenterologist, Clínica San Felipe, Lima, Peru.

Julissa Mirella Guevara Miranda, Clínica San Felipe

Gastroenterologist, Clínica San Felipe, Lima, Peru.

Jaime Augusto Cáceres Pizarro, Hospital Nacional Cayetano Heredia

Pathologist, Hospital Nacional Cayetano Heredia, Lima, Peru.

References

Rubio-Tapia A, Herman ML, Ludvigsson JF, Kelly DG, Mangan TF, Wu TT, et al. Severe spruelike enteropathy associated with olmesartan. Mayo Clin Proc. 2012;87(8):732–8. https://doi.org/10.1016/j.mayocp.2012.06.003

Kamal A, Fain C, Park A, Wang P, Gonzalez-Velez E, Leffler DA, et al. Angiotensin II receptor blockers and sprue-like enteropathy: a systematic review. Gastroenterol Rep (Oxf). 2019;7(3):162–7. https://doi.org/10.1093/gastro/goz019

Ianiro G, Bibbò S, Montalto M, Ricci R, Gasbarrini A, Cammarota G. Systematic review: sprue-like enteropathy associated with olmesartan. Aliment Pharmacol Ther. 2014;40(1):16–23. https://doi.org/10.1111/apt.12780

Schiepatti A, Sanders DS, Baiardi P, Caio G, Ciacci C, Kaukinen K, et al. Nomenclature and diagnosis of seronegative coeliac disease and chronic non-coeliac enteropathies in adults: the Paris consensus. Gut. 2022;71(11):2218-25. https://doi.org/10.1136/gutjnl-2021-326645

Negro A, Blanco I. A case of severe sprue-like enteropathy associated with losartan. J Clin Gastroenterol. 2015;49(9):794–5. https://doi.org/10.1097/MCG.0000000000000383

Mazhar A, Arnautovic J. Losartan-induced sprue-like enteropathy. Am J Gastroenterol. 2017;112(Suppl):S1359. https://doi.org/10.14309/00000434-201710001-02424

Marietta EV, Nadeau AM, Cartee AK, Singh I, Rishi A, Choung RS, et al. Immunopathogenesis of olmesartan-associated enteropathy. Aliment Pharmacol Ther. 2015;42(11–12):1303–14. https://doi.org/10.1111/apt.13413

U.S. Food and Drug Administration [Internet]. FDA Drug Safety Communication: FDA approves label changes to include intestinal problems (sprue-like enteropathy) linked to blood pressure medicine olmesartan medoxomil. Silver Spring: FDA; 2013 [citado el 4 de enero de 2026]. Disponible en: https://www.fda.gov/media/86382/download

Dreifuss SE, Tomizawa Y, Farber NJ, Davison JM, Sohnen AE. Spruelike enteropathy associated with olmesartan: an unusual case of severe diarrhea. Case Rep Gastrointest Med. 2013;2013:618071. https://doi.org/10.1155/2013/618071

Herman ML, Rubio-Tapia A, Wu TT, Murray JA. A case of severe sprue-like enteropathy associated with valsartan. ACG Case Rep J. 2015;2(2):92–94. https://doi.org/10.14309/crj.2015.15

Menne J, Haller H. Olmesartan and intestinal adverse effects in the ROADMAP study. Mayo Clin Proc. 2012;87(12):1230-1. https://doi.org/10.1016/j.mayocp.2012.10.005

DeGaetani M, Tennyson CA, Lebwohl B, Lewis SK, Abu Daya H, Arguelles-Grande C, et al. Villous atrophy and negative celiac serology: a diagnostic and therapeutic dilemma. Am J Gastroenterol. 2013;108(5):647-53. https://doi.org/10.1038/ajg.2013.45

Figure 1. Video capsule endoscopy. A. Villous atrophy in the duodenum. B. Villous atrophy in the jejunum

Published

2026-09-11

How to Cite

Chávez Sánchez, S. A., Espinoza Ríos, J. L., Pinto Valdivia, J. L., Guevara Miranda, J. M., & Cáceres Pizarro, J. A. (2026). Losartan-induced sprue-like enteropathy: A case report. Revista Colombiana De Gastroenterología, 41(3), 379–382. https://doi.org/10.22516/25007440.1532

Altmetric

Escanea para compartir
QR Code
Crossref Cited-by logo
Article metrics
Abstract views11
Galley views2
PDF Views2
HTML views0
Other views0

Some similar items: